The aim of the present study was to retrospectively analyse the variability of uptake of the radiolabelled PSMA‐ligand [18F]PSMA‐1007 in organs at risk, and secondary to investigate the relationship between the uptake in organs at risk and tumour burden, in patients who underwent PET‐CT for the management of prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.